2016

Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept

Franke, B

Nature Publishing Group

info:eu-repo/semantics/article
© Nature America, Inc.
All rights reserved
http://doi.org/10.1038/nn.4228

https://erepo.uef.fi/handle/123456789/154
Downloaded from University of Eastern Finland's eRepository
Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof-of-concept and roadmap for future studies


2 Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
3 Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands
4 Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands
5 Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
6 Neurogenetics Program, Department of Neurology, UCLA School of Medicine, Los Angeles, USA
7 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
8 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
9 Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, CCM, Berlin, Germany
10 Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands
11 Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspond with: Barbara Franke, PhD, Department of Human Genetics (855), Radboud University Medical Center, Nijmegen, The Netherlands. V: +31-24-3610181; Email: barbara.franke@radboudumc.nl

Conflict of Interest
Several of the authors/contributors are employees of companies: Johnson and Johnson, Pfizer (C.R.S., J.R.W., H.S.X), F. Hoffman-La Roche (E.D., L.E), Eli Lilly (D.C., Y.M., L.N), Janssen (S.G., D.W., Q.S.L.), and deCODE genetics (S.G., K.S., H.S.). P.F.S is a scientific advisor to Pfizer. None of these companies influenced the design of the study, the interpretation of the data, the amount of data reported, or financially profit by publication of these pre-competitive results. The other authors do not report conflicts of interest.

Published in final edited form as:
Abstract

Schizophrenia is a devastating psychiatric illness with high heritability. Brain structure and function differ, on average, between schizophrenia cases and healthy individuals. As common genetic associations are emerging for both schizophrenia and brain imaging phenotypes, we can now use genome-wide data to investigate genetic overlap. Here we integrated results from common variant studies of schizophrenia (33,636 cases, 43,008 controls) and volumes of several (mainly subcortical) brain structures (11,840 subjects). We did not find evidence of genetic overlap between schizophrenia risk and subcortical volume measures either at the level of common variant...
genetic architecture or for single genetic markers. The current study provides proof-of-concept (albeit based on a limited set of structural brain measures), and defines a roadmap for future studies investigating the genetic covariance between structural/functional brain phenotypes and risk for psychiatric disorders.

Keywords
schizophrenia; MRI; brain imaging; genetics; GWAS; meta-analysis; endophenotype

Introduction

Schizophrenia is a devastating, highly heritable psychiatric disorder that affects approximately 1% of the population. Despite marked recent successes in identifying genetic risk factors and pathways involved in schizophrenia, the neurobiology of schizophrenia remains poorly understood.

Many differences in brain function and structure have been reported in cases with schizophrenia compared with controls, although there is considerable inter-individual heterogeneity. Of specific relevance to this study, a recent meta-analysis found that schizophrenia cases had smaller hippocampus, amygdala, thalamus, nucleus accumbens, and intracranial volumes along with larger pallidum and lateral ventricle volumes. Hippocampal and lateral ventricle volumes were influenced by antipsychotic medication use. In addition, mean hippocampal volume is smaller in high-risk individuals and in unaffected first-degree relatives of schizophrenia cases.

Structural brain measurements, such as those from magnetic resonance imaging (MRI), typically have high reproducibility and low measurement error and can be highly heritable. Increasingly large studies of brain morphometry are being performed, and are being used to evaluate the effects of common and rare genetic contributions on brain structure.

With genome-wide association results available from large samples for schizophrenia and for MRI-based brain phenotypes, we can now use genomic approaches to evaluate the genetic link between disease risk and such brain measures. Findings of covariation would help us develop new hypotheses about the structures involved in the primary disease process of schizophrenia. In this proof-of-concept study, we created a roadmap for the analysis of genetic covariation using a battery of complementary methods. We evaluated the overlap of common genetic variation at the high level of genetic architecture as well as of individual genetic variants. We also evaluated common genetic variant effect sizes on neuroimaging phenotypes and schizophrenia. The data we analyzed are from large mega-analyses by the PGC (Psychiatric Genomics Consortium) for schizophrenia and meta-analyses from the ENIGMA consortium (Enhancing NeuroImaging Genetics through Meta-Analysis) for eight MRI volumetric measures (amygdala, caudate nucleus, hippocampus, nucleus accumbens, pallidum, putamen, thalamus, and intracranial volume (ICV)). Our results suggest that common genetic variation predisposing to schizophrenia does not show evidence of overlap...
Results

We analyzed genome-wide association data for schizophrenia (33,636 cases and 43,008 controls) and eight structural MRI brain measures (11,840 individuals). Sample characteristics are presented in *Supplementary Table 1*. These data were used for a comprehensive set of comparisons of common variant genetic sharing between schizophrenia and brain volumetric measures.

Comparisons of common variant genetic architectures

**Linkage disequilibrium score regression (LDSR)**—Using GWA summary statistics (excluding the extended MHC region), we used LDSR to estimate the heritability of schizophrenia due to common SNPs at 25.5% (SE=1.1%) along with eight brain volumetric measures (*Table 1*). The SNP-based heritability estimates for the MRI measures ranged from 11% (nucleus accumbens) to 30% (putamen). The heritability for amygdala volume was non-significant in this sample. The genetic correlations of MRI volumetric measures with schizophrenia were all non-significant (*Table 1*). These negative findings stand in contrast to the relatively high common-variant correlations of schizophrenia with bipolar disorder and major depressive disorder.\(^{13}\)

**Genetic predisposition scores**—In the genetic “risk” score approach,\(^{15}\) we considered the ENIGMA GWA results as “training” sets in order to compute common variant genetic predisposition to (for instance) greater ICV for each schizophrenia case and control. We then compared the mean polygenic predisposition score in cases to that in controls. None of the correlations was significant after correction for eight comparisons (*Figure 1* and *Table 2*). The strongest effect (for hippocampal volume) was almost entirely driven by one SNP (rs2268894),\(^3\) but only three SNPs met the p-value threshold of \(1 \times 10^{-6}\) for inclusion in this analysis. These null results are in contrast to the robust evidence for common variant genetic correlations between schizophrenia and other psychiatric disorders.\(^{16}\)

**Rank-rank hypergeometric overlap test (RRHO)**\(^{17}\)—We quantified overlap between pairs of GWA results ranked by their association statistics using RRHO based on 172,652 SNPs. The overlap of rank-ordered lists of genetic variants influencing any of the brain MRI volumes and those conferring risk for schizophrenia was not statistically significant (*Figure 2*). The overlap between genetic contributions to putamen and caudate nucleus volumes was used as a positive control; the overlap between genetic contributions to hippocampal volume and the presumably unrelated trait of thumb whorl structure\(^{18}\) was used as a negative control. The latter comparison showed similar overlap to that of brain structure and schizophrenia.

**Sign tests**

We compared the pattern of GWA results by checking whether the signs of the regression coefficients\(^3\) were consistently in the same direction between the top associations for
schizophrenia and those for the MRI volumetric measures. None of the sign tests showed consistent directions of effect (Table 3).

**Analysis of single genetic variants**

**Genome-wide significant associations**—We evaluated the 128 genome-wide significant schizophrenia index SNPs for association with brain volumes. One association survived correction for 876 comparisons: rs2909457*A (chr2:162,845,855, intergenic between SLC4A10 and DPP4) was associated with decreased hippocampal volume ($P=1.2 \times 10^{-6}$, effect size=−23 mm$^3$ per allele) and decreased risk for schizophrenia (odds ratio=0.94, $P=4.6 \times 10^{-8}$). However, this finding was in the opposite direction of expectations given previous observations of smaller hippocampal volumes in cases relative to controls (Supplementary Table 2). Starting with the eight SNPs previously found associated with the brain volumes, no significant associations with schizophrenia were observed (Supplementary Table 2).

**SNP meta-analyses**—We also performed GWA meta-analyses of the schizophrenia and brain structure results. The Manhattan plots for these analyses are shown in Supplementary Figures 1-8. In Supplementary Table 3, the genome-wide significant findings are given. In most instances, the results were entirely driven by the association with schizophrenia.

**Conjunction analysis**—To identify individual SNPs that influence risk for both schizophrenia and brain structure, we implemented a conjunction test. No SNP showed genome-wide significant association with both schizophrenia and brain structure, although several loci were detected at sub-threshold levels (Supplementary Figure 9).

**Comparison of genetic effect sizes for clinical and brain volume measures**

Some investigators have suggested that common genetic variants underlying continuous brain imaging endophenotypes may have larger effect sizes than those for neuropsychiatric disorders (e.g., schizophrenia). To test this hypothesis, we compared the maximum effect sizes from replicated genetic associations for each trait. For comparability across quantitative or binary traits, effect sizes were assessed as percent of variance explained (for MRI volumes) or percent of variance explained on the liability scale (for schizophrenia). As shown in Supplementary Figure 10, individual common variants had only a small influence on either brain structure or schizophrenia. Effect sizes for individual SNPs were similar for both brain structure and schizophrenia, and of the same order as those observed for anthropometric traits such as height.

**Discussion**

In this proof-of-concept study, we evaluated the relationship between common genetic variants implicated in schizophrenia and those associated with subcortical brain volumes and ICV. The sample sizes were the largest yet applied to these questions. With a comprehensive set of analyses, we did not find evidence for notable genetic correlations, either at a high level (i.e., common variant genetic architecture) or for single genetic markers. Our findings do not support the hypothesis that these subcortical brain volume measures and ICV are
causally associated with schizophrenia risk. Similarly, we did not find evidence that common SNPs have pleiotropic effects on these MRI volumes and schizophrenia. Our results suggest alternative hypotheses that require consideration and refutation – that the volumetric differences observed in schizophrenia cases may be epiphenomena unrelated to its primary genetic causes, a result of prenatal environment, or result from reverse causation. Finally, the effect sizes of SNPs implicated in schizophrenia and those associated with brain volumes were broadly similar.

We studied a limited set of brain MRI measures. Our study should be considered a proof-of-concept for evaluating genetic covariation rather than decisively addressing the full range of hypotheses pertaining to the genetic overlap of brain imaging measures with neuropsychiatric disease risk. We provide a rigorous roadmap for more definitive and larger future studies. Full elucidation of the brain correlates of schizophrenia will require a fuller set of structural and functional imaging measures (perhaps at the voxel level) along with evaluation of common and rare genetic variation.

The null findings of this study should be interpreted in light of several qualifiers. First, several brain regions that are not expected a priori to overlap with schizophrenia were included for completeness (e.g., caudate and putamen volumes are uncorrelated with schizophrenia, and amygdala volume did not have SNP-heritability different from zero in our study). Second, other neuroimaging phenotypes could be more informative for schizophrenia (e.g., cortical thickness, ventricular volume, diffusion tensor imaging, or functional activity). Indeed, genetic variants associated with disease may influence distinct cell types within circumscribed neural circuits that may not be captured by MRI. Third, the ENIGMA MRI protocol served to harmonize images obtained from different scanners and protocols. While we have shown this performs well, genetic signal might have been lessened. Fourth, in this study of adults, we may not have observed the brain regions at the most appropriate time for identifying genetic overlap with schizophrenia, given that the volumes of most subcortical brain structures plateau in late adolescence to early adulthood. While schizophrenia is widely believed to be a neurodevelopmental disorder, its onset generally follows the period of greatest growth for these structures. Fifth, relatively small genetic correlations between schizophrenia and these brain volumes may have been masked by combining datasets in a meta-analytic framework (e.g., heterogeneous sample characteristics such as age, sex, and technical noise resulting from different MRI scanners or acquisition sequences may remain). It is conceivable that this resulted in the lower than expected SNP-heritability for some of these measures. Mega-analysis could be an important way to improve control for heterogeneity. Sixth, we evaluated only common genetic variation. Although common genetic variation explains far more of the risk for schizophrenia than rare copy number variation or rare deleterious exonic variation, rare genetic effects on brain structure could be salient for some cases of schizophrenia. Finally, the sample sizes and statistical power of the schizophrenia and neuroimaging data sets differed. The PGC has attained a sample size sufficient to detect many common loci of small effect, whereas ENIGMA is earlier in the discovery arc.

Brain volume heritability estimates from genome-wide data obtained using LDSR were lower than observed in previous studies. This was expected for the subcortical regions, as
those were corrected for ICV. For ICV, a likely source of difference with previous studies is the removal of the extended MHC region from our analysis.

Although we found no evidence for genetic correlation between subcortical volumes and schizophrenia, we also investigated whether effect sizes of genetic variants are larger for brain measures than for schizophrenia. This point has been debated with respect to “endophenotype” studies, which attempt to identify quantifiable brain measures or other biomarkers thought to be intermediate between genotype and the liability to a disorder. An endophenotype that lies on a causal pathway to a clinical disorder could increase power for genetic studies. Prior studies addressed this hypothesis in far smaller samples. We compared SNP effect sizes for the top findings for schizophrenia with those for subcortical volumes (hippocampus, putamen, caudate) and ICV. The results of this analysis showed similar effect sizes. Importantly, the endophenotype concept is unlikely to be sufficiently addressed in these analyses given the reasons noted above.

In conclusion, this paper presents a roadmap for comprehensive evaluation of genetic covariation between neuropsychiatric disease liability and brain imaging measures. The current analysis was limited to a small number of brain volume phenotypes, and no evidence of genetic overlap was identified. More extensive brain-wide and genome-wide analyses may help in the mechanistic dissection of genetic risk for disease.

Online Methods

A supplementary methods checklist is available. The data used for the analyses described here are available to researchers. The ENIGMA data can be obtained from http://enigma.ini.usc.edu/enigma-vis. The PGC data can be downloaded from http://www.med.unc.edu/pgc/downloads.

PGC schizophrenia

We mega-analyzed individual genotype data from 46 European-ancestry schizophrenia GWAS datasets (full details in reference 3). Briefly, quality control and imputation were performed by the PGC Statistical Analysis Group for each dataset separately. Genotype imputation was with the pre-phasing/imputation stepwise approach implemented in IMPUTE2/SHAPEIT (chunk size of 3 Mb and default parameters) using the 1000 Genomes Project dataset (phase 1, August 2012, URLs). After imputation, we identified autosomal SNPs with high imputation accuracy across all samples. For robust relatedness testing and population structure analysis, we evaluated a subset of SNPs following LD-pruning ($r^2 > 0.02$ and frequency filtering (MAF > 0.05). For association testing, we evaluated the 46 datasets separately using an additive logistic regression model including ancestry principal components as covariates, and then conducted a meta-analysis of the 52 sets of results using an inverse-weighted fixed effects model. After excluding subjects who were also in ENIGMA (N=458, see below), 33,636 cases and 43,008 controls were used for calculations (Supplementary Table 1).
ENIGMA, sample with brain volume measures and assessment of endophenotype

The data analyzed here are from the ENIGMA analysis of eight MRI volumetric measures (full details in reference 9). MRI brain scans and genome-wide genotype data were available for 11,840 subjects from 22 cohorts (Supplementary Table 1). Only cohorts without schizophrenia cases and controls overlapping with the PGC schizophrenia samples were included. Participants clustered with subjects of known European ancestry as verified by multidimensional scaling (MDS) analysis. Genomic data were imputed to a reference panel (1000 Genomes, v3 phase1) comprising only European samples and with monomorphic SNPs removed. Imputation was performed at each site using MaCH for phasing and minimac for imputation. Only SNPs with an imputation score of RSQ > 0.5 and minor allele counts > 10 within each site were included. Tests of association were conducted separately for eight MRI volumetric phenotypes (nucleus accumbens, amygdala, caudate nucleus, hippocampus, pallidum, putamen, thalamus, and ICV) with the following covariates in a multiple linear regression framework: age, age^2, sex, 4 MDS components (to account for population structure), ICV (for subcortical brain phenotypes), and diagnosis (when applicable). The GWA statistics from each of the 22 sites were combined using a fixed-effect inverse variance-weighted meta-analysis as implemented in METAL.

Removal of duplicated individuals

Subject overlap between all PGC and ENIGMA cohorts was evaluated using a checksum algorithm in order to ensure the robustness of our results given that some analyses were sensitive to the presence of duplicate individuals. For each individual, ten checksum numbers were created based on ten batches of 50 SNP genotypes and compared between individuals from both consortia. Based on these comparisons and a general exclusion of cohorts containing schizophrenia cases, 1,517 individuals were removed from ENIGMA and 458 subjects were removed from the PGC.

Linkage disequilibrium score regression (LDSR)

For LDSR, each dataset underwent additional filtering. Only markers overlapping with HapMap Project Phase 3 SNPs and passing the following filters were included: INFO score > 0.9 (where available), study missingness of 0, and MAF >1%. Indels and strand-ambiguous SNPs were removed. To remove a potential source of bias, all SNPs in the extended MHC region (chr6:25-35 Mb) were removed from all datasets. The schizophrenia analysis included only results from European studies were used (LDSR requires LD data from a comparable sample). For the ENIGMA amygdala results, the mean \( \chi^2 \) was too low (1.0051) to reliably estimate heritability using LDSR.

The analysis was conducted using a two-step procedure with the LD-scoring analysis package. An unconstrained regression was run to estimate the regression intercepts for each phenotype, followed by an analysis with regression intercepts constrained to those estimated in the first step and the covariance intercept defined as zero (note that we took steps to exclude overlapping samples). Standard errors were estimated using a block jackknife procedure and used to calculate \( P \)-values.
Genetic predisposition analyses

To investigate the combined impact of ENIGMA association results on case-control status in the PGC schizophrenia data, we performed a series of genetic predisposition score analyses. For each ENIGMA volumetric phenotypes, we excluded SNPs with MAF <2%, indels, and SNPs in the extended MHC region (chr6:25-34 Mb). We then “clumped” the data, discarding variants within 500 kb of and in $r^2 \geq 0.1$ with another more significant marker. We performed genetic predisposition score prediction of target subgroups as originally described\textsuperscript{15} for several $P$-value thresholds ($5 \times 10^{-8}$, $1 \times 10^{-6}$, $1 \times 10^{-4}$, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5, 1.0), multiplying the effect size of the ENIGMA phenotype of each variant by the imputation probability for the risk allele in each individual. The resulting values were summed so that each individual had a genetic predisposition score for further analyses. Two outcome variables are reported in Table 2: the significance of the case-control score difference analyzed by logistic regression (including ancestry-based principal components and a study indicator as covariates) and the proportion of variance explained (Nagelkerke’s $R^2$) computed by comparison of a full model (covariates + polygenic risk scores) score to a reduced model (covariates only). Note that these $R^2$ estimates are biased due to recruitment of the case-control studies and as the numbers of cases and controls do not reflect the underlying risk of disease in the population.

Rank-rank-hypergeometric overlap test (RRHO)

RRHO\textsuperscript{17} tests the hypothesis that ordering of two lists (LD-pruned GWAS results for schizophrenia versus a brain structure phenotype) by the strength of their association is arbitrary. The number of independent SNPs in common between the two ordered lists is evaluated at specified step sizes. Two lists that show similar ordering of SNPs demonstrate a global pattern of similarity of associations. Independent SNPs were selected based on the 1000 Genomes European dataset for 200 SNP windows shifted at five SNP intervals using an $r^2$ threshold of 0.25. SNPs found in both PGC and ENIGMA data with MAF $\geq 0.01$ were retained (172,652 SNPs). The SNPs were then ordered by the $-\log_{10}(p$-value) of association multiplied by the effect size. A two-sided RRHO test that allowed testing for either over- or under-enrichment was used with a step-size of 3000 SNPs.

Finger whorl data used as control in conjunction analysis

A GWAS of a dermatoglyphic trait (presence of a whorl on the left thumb), collected as part of an ongoing study at the Queensland Institute of Medical Research,\textsuperscript{18} was used to provide a negative control for the RRHO test. Briefly, rolled ink prints were collected on archival quality paper, and fingerprint patterns were manually coded. Complete data from 3,314 participants (twins and their family members) were available. Genotypes were imputed to the 1000 Genomes Project reference (phase 1 version 3). GWAS was conducted using Merlin-offline to account for relatedness and zygosity.

Lookup of top GWAS SNP findings

Evidence for an effect of the reported 128 independent schizophrenia-associated SNPs on subcortical brain volumes and ICV was studied through a look-up of results. rs115329265 was not available in the ENIGMA data and was replaced by a SNP in moderate LD
(chr6:28305863R; r²=0.64); rs77149735 was not available in ENIGMA and could not be replaced by a SNP in LD. Three chrX SNPs (rs1378559, rs5937157, and rs12845396) were excluded, because chrX data were not available from ENIGMA. Effects of the eight independent SNPs associated with brain volumes reported by ENIGMA on schizophrenia risk were studied through a look-up of results in the PGC data.

Multiple comparison correction was performed by estimating the effective number of independent tests (Meff). This method considers the correlation structure (Supplementary Table 4) between brain measures and calculates the Meff based on the observed eigenvalue variance of the different brain volume measures using matSpD (see URLs). The p-value for significance was 0.05 divided by the sum of (a) Meff times the number of SNPs included in the lookup from PGC to ENIGMA (n=124), and (b) the number of SNPs included in the lookup from ENIGMA to PGC (n=8). Eight brain volumes resulted in seven independent tests, and only SNPs with a P < 5.7×10⁻⁵ were considered significant.

**SNP sign test in the top GWAS findings**

To investigate a potential accumulation of same or opposite direction effects of SNPs between PGC schizophrenia and ENIGMA, we counted the number of same direction effects for the top-findings from the schizophrenia dataset (94 LD-independent genome-wide significant SNPs, 231 with P < 1×10⁻⁶) in the different brain structure datasets and tested the significance of the result in a binomial test (n=14 tests for 7 effective ENIGMA phenotypes and 2 P-value thresholds).

**Conjunction analysis**

To determine whether a particular SNP is linked to both brain structure and risk for schizophrenia, a conjunction analysis was used. This analysis makes inference on the alternative hypothesis that both null hypotheses are false. This is in distinction to a traditional meta-analysis method which infers on an alternative hypothesis that one or more null hypotheses are false. A conjunction analysis is calculated as: $P_{conj} = \max(P_{brain}, P_{case-control})$, where $P_{brain}$ is the significance of the SNP associated to brain structure and $P_{case-control}$ is the significance of the SNP association to schizophrenia. As conjunction tests can be very conservative, an adjustment to this test based on the estimated fraction of false nulls was used here with modifications ($P'_{conj}$). Over 7.5 million SNPs found in both the ENIGMA and PGC datasets with MAF ≥0.01 were evaluated.

A conjunction null hypothesis is the union of the individual null hypotheses, producing a ‘composite null hypothesis’. In standard testing situations a “point null hypothesis” is used, meaning that there is exactly one configuration of the unknown parameters of interest that corresponds to the null. For example, “no gene-brain association, no case-control association” is a point null hypothesis. A composite null has multiple configurations. For example, both of these configurations fall into the conjunction null hypothesis: “true gene-brain association, no case-control association”; “no gene-brain association; true case-control association”. A valid conjunction test has to control false positive risk over all possible configurations in the conjunction null. Put another way, a conjunction test has to be
calibrated for the worst possible configuration of true signals, and as a result can be quite conservative when the true state of the model is not one of the extreme cases.

The method of Deng et al.\textsuperscript{36} attempts to reduce the conservativeness of the conjunction procedure in the multiple testing setting. The authors propose a method that estimates prevalence of null hypotheses in each of the individual tests being combined. With this information, a “relaxed” test can be constructed that is less conservative. However, a crucial equation in that paper is in error. The equation below provides the estimator for the proportion of false null hypothesis for each of the two tests to be combined. The expression is based on the method of Storey\textsuperscript{37}, who posed it as an estimate of the proportion of true null hypotheses. Deng et al.\textsuperscript{36} apparently inverted the result incorrectly; the correct expression is:

$$\hat{\pi}_i(\lambda) = 1 - \frac{\# \{p_i(j) > \lambda\}}{(1 - \lambda) n}$$

In our analyses, the $\lambda$ parameter in the equation above was set to 0.25.

**SNP meta-analysis**

We combined the association $P$-values of SNPs associated with schizophrenia with SNPs associated with the seven subcortical brain volumes and ICV from ENIGMA. Using METAL,\textsuperscript{35} we conducted a sample size-weighted meta-analysis for schizophrenia (effective sample size 71,715) and ENIGMA (variable sample sizes per SNP ranging from 8,000-11,000). SNPs were excluded if they were not present in both datasets and for MAF < 1% (per analysis). The total number of SNPs present in the eight meta-analyses ranged from 7,847,762 to 7,945,194.

**SNP effect size comparisons**

SNP effect sizes were extracted from studies of brain structure (ENIGMA),\textsuperscript{9} schizophrenia (PGC),\textsuperscript{3} height (G I A N T),\textsuperscript{24} and educational attainment (EduYears).\textsuperscript{38} The five highest effect size SNPs were selected for schizophrenia and height, all genome-wide significant SNPs were displayed for brain structure volumes and EduYears. Percent variance was calculated on the liability scale for schizophrenia for comparison with quantitative traits.\textsuperscript{23} For brain structures, height, and EduYears, percent variance explained was calculated as $R^2_{g|c} (1-R^2_c) = (t^2/((n-k-1)+t^2))*100$, where the $t$-statistic is calculated as the $\beta$-coefficient for a given SNP from the regression model (controlling for covariates) divided by the standard error of the $\beta$-estimate, n is the total number of subjects, and k is the total number of covariates. 95% confidence intervals were calculated by transforming percent variance explained to a $Z$-statistic using Fisher’s $Z$ transformation, finding the 95% confidence intervals of the $Z$-statistic, and transforming this interval back into percent variance explained.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.
Acknowledgements

Psychiatric Genomics Consortium (PGC). The authors are grateful to the many family members who participated in the studies that recruited these samples, to the many clinicians who assisted in their recruitment, and to our team members without whom this study would have been impossible. Core funding for the PGC is from the US National Institute of Mental Health (U01 MH094421). Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara and financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam. The GRAS data collection was supported by the Max Planck Society, the Max-Planck-Förderstiftung, and the DFG Center for Nanoscale Microscopy & Molecular Physiology of the Brain (CNMPB), Göttingen, Germany. The Boston CIDAR project was supported by the NIMH (P50 MH080272, RWM; U01 MH081928, LJS; R01 MH092380, TLP) and the Massachusetts General Hospital Executive Committee on Research (TLP). P.H.L. is supported by NIMH K99 MH101367. ISC Portugal: CNP and MTP have been supported by NIMH grants MH085548, MH085542, MH071681, MH061884, MH58693, and MH52618, and the NCRR RR026075. CNP, MTP, and AHP have been supported by grants from the Department of Veterans Affairs Merit Review Program. The Danish Aarhus study was supported by grants from Lundbeck Foundation, Danish Strategic Research Council, Aarhus University, and Stanley Research Foundation. Work in Cardiff was supported by MRC Centre (G0800509) and MRC Programme (G0801418) Grants, the European Community's Seventh Framework Programme (HEALTH-F2-2010-241909, Project EU-GEI) the European Seventh Framework Programme (FP7/2007-2013) under grant agreement n°279227, a fellowship to JW from the MRC/Welsh Assembly Government and the Margaret Temple Award from the British Medical Association. We thank Novartis for their input in obtaining CLOZUK samples, and staff at The Doctor's Laboratory (Lisa Levett/Andrew Levett) for help with sample acquisition and data linkage, and in Cardiff (Kiran Mantripuragada/Lucinda Hopkins) for sample management. CLOZUK and some other samples were genotyped at the Broad Institute or by the WTCCC and WTCCC2 (WT 083948/Z0072). We acknowledge use of the British 1958 Birth Cohort DNA (MRC: G0000934) and the Wellcome Trust (068545/Z05/ and 076133/C04/Z), the UK Blood Services Common Controls (UKBCC collection), funded by the WT (076113/C04/Z) and by NIHR programme grant to NHSBT (RP-PG-0310-1002). VCU investigators were supported by NIMH grants R01 MH083094, R01 MH041953, and R01 MH068881, and WTCCC2 grant WTCCC-084710. Recruitment of families in Bulgaria was funded by the Janssen Research Foundation, Beersel, Belgium. We thank the staff in the Neuroscience Biomarkers Genomic Lab led by Reyna Favis at Janssen for sample processing and the staff at Illumina for genotyping Janssen DNA samples. We also thank Anthony Santos, Nicole Bottrel, Monique-Andree Franc, William Cafferty of Janssen Research & Development) for operational support. Funding from the Netherlands Organization for Health Research and Development (ZonMW), within the Mental Health program (GROUP consortium), and NIMH R01 MH078075. The Danish Council for Strategic Research (Journ.nr. 09-067048); The Danish National Advanced Technology Foundation (Journ.nr. 001-2009-2); The Lundbeck Foundation (Journ nr. R24-A2343); EU 7th Framework Programme (PsychGene; Grant agreement nr. 218251); EU 7th Framework Programme (PsychDPC; Grant agreement nr. 286213). The Wellcome Trust supported this study as part of the WTCCC2 project. E. Bramon holds a MRC New Investigator Award and a MRC Centenary Award. The TOP Study was supported by the Research Council of Norway (#213837, # 217776, # 223273), South-East Norway Health Authority (#2013-123) and K.G. Jebsen Foundation. This work was supported by the Donald and Barbara Zucker Foundation, the North Shore – Long Island Jewish Health System Foundation, and grants from Stanley Foundation (AKM), NARSAD (AKM), NIMH (MH065580 to TL; MH001760 to AKM), and NIMH R01 MH084998. SynSys, EU FP7-242167, Sigrid Juselius Foundation, The Academy of Finland (grant number: 251704), Sohlberg Foundation. The Swedish Research Council (grants 2006-4472, 2009-5269, 2009-3413) and the County Councils of Västerbotten and Norrbotten, Sweden supported the collection of the Umeå samples. The Betula Study, from which the Umeå controls were recruited, is supported by grants from the Swedish Research Council (grants 345-2003-3883, 315-2004-6977) and the Bank of Sweden Tercentenary Foundation, the Swedish Council for Planning and Coordination of Research, the Swedish Council for Research in the Humanities and Social Sciences and the Swedish Council for Research. We acknowledge support from NIMH R01 MH085812 (PI Keller) and NIMH R01 MH100141 (PI Keller). EGUCUT work was supported by the Targeted Financing from the Estonian Ministry of Science and Education (SF0180142008); NIH R01 DK075787; the Development Fund of the University of Tartu (grant SPIGVARENG); the European Regional Development Fund to the Centre of Excellence in Genomics (EXCEGEN; grant 3.2.0304.11-0312); and FP7 grant 313010. MM was supported by CZ.2.16/3.1.00/24022OOPK, NT/13770-4and 00664203 FN Motol. Funding from the National Medical Research Council (NMRC/TRC/003/2008) and the Biomedical Research Council (A*STAR) is acknowledged. Genotyping of the Swedish Hubin sample was performed by the SNP&SEQ Technology Platform in Uppsala, which is supported by Uppsala University, Uppsala University Hospital, Science for Life Laboratory, and the Swedish Research Council (Contracts 80576801 and 70374401). The Swedish Hubin sample was supported by Swedish Research Council (IA, EGG) and Stockholm County Council and the Karolinska Institutet (EGJ). B.J.M., V.J.C., R.J.S., S.V.C., F.A.H., A.V.J., C.M.L., P.T.M., C.P., and U.S. were supported by the Australian Schizophrenia Research Bank, which is supported by an Enabling Grant from the National Health and Medical Research Council (No. 386500), the Pratt Foundation, Ramsay Health Care, the Vietrle Charitable Foundation and the Schizophrenia Research Institute and the NSW Department of Health. C.P. is supported by a Senior Principal Research Fellowship from the National Health and Medical Research Council (Australia). The Perth sample collection was funded by Australian National Health and Medical Research Council project grants and the Australian Schizophrenia Research Bank. The Bonn/Mannheim sample was genotyped within a study that was...
supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network (IG) MoodS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia; grant 01GS08144 to M.M.N. and S.C., grant 01GS08147 to M.R.), under the National Genome Research Network plus (NGFNplus), and the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under e:Med Programme (GSK control sample; Müller-Myhosk). This work has been funded by the Bavarian Ministry of Commerce and by the Federal Ministry of Education and Research in the framework of the National Genome Research Network, Förderkennzeichen 01GS0481 and the Bavarian Ministry of Commerce. M.M.N. is a member of the DFG-funded Excellence-Cluster ImmunoSensation. M.M.N. also received support from the Alfréd Krupp von Bohlen and Halbach-Stiftung. M.R. was supported by the 7th Framework Programme of the European Union (ADAMS project, HEALTH-F4-2009-242257, CRESTART project, HEALTH-2011-1.1-2) grant 279227. J.K. holds the Joanne Murphy Professor in Behavioural Science. The Stanley Center for Psychiatric Research at the Broad Institute acknowledges funding from the Stanley Medical Research Institute. Support for the Sweden Schizophrenia Study (Pls Sullivan, Hultman, and Sklar) was provided by the NIMH (R01 MH077139 and R01 MH095034), the Stanley Center for Psychiatric Research, the Sylvan Herman Foundation, the Friedman Brain Institute at the Mount Sinai School of Medicine, the Karolinska Institutet, Karolinska University Hospital, the Swedish Research Council, the Swedish County Council, the Söderström Königska Foundation. We acknowledge use of DNA from The UK Blood Services collection of Common Controls (UKBS collection), funded by the Wellcome Trust grant 076113/C104/Z, by the Juvenile Diabetes Research Foundation grant WT061838, and by the National Institute of Health Research of England. The Multicenter Genetics Studies of Schizophrenia and Molecular Genetics of Schizophrenia studies study were supported by NIMH grant R01 MH062276 (to DF Levinson, C Laurent, M Owen and DD Widenauer), grant R01 MH068922 (to PV Gejman), grant R01 MH068921 (to AE Pulver) and grant R01 MH068881 (to B Riley). D.F.L. was supported by the Walter E. Nichols, M.D., Professorship in the School of Medicine, the Eleanor Levinson Professorship in the School of Medicine, the Walter F. & Rachael L. Nichols Endowment and the William and Mary McIvor Endowment, Stanford University. This study was supported by NIH R01 grants (MH67257 to N.G.B., MH59588 to B.J.M., MH59571 to P.V.G., MH59565 to R.F., MH59587 to F.A., MH60870 to W.F.B., MH59566 to D.W.B., MH59586 to J.M.S., MH61675 to D.F.L., MH60879 to C.R.C., and MH58100 to P.V.G.), NIH U01 grants (MH46276 to C.R.C., MH46289 to C. Kaufmann, MH46318 to M.T. Tsuang, MH79469 to P.V.G., and MH79470 to D.F.L.), the Genetic Association Information Network (GAIN), and by The Paul Michael Donovan Charitable Foundation. Genotyping was carried out by the Center for Genotyping and Analysis at the Broad Institute of Harvard and MIT (S. Gabriel and D. B. Mirel), supported by grant U54 RR020728 from the National Center for Research Resources. We thank S. We (DRW, RS) thank the staff of the Lieber Institute and the Clinical Brain Disorders Branch of the IRP, NIMH for their assistance in data collection and management. We acknowledge the Irish contribution to the International Schizophrenia Consortium (ISC) study, the WTCC2 SCZ study & WTCC2 controls from the 1958BC and UKNBS, the Science Foundation Ireland (08/IN.1/B1916). We acknowledge use of the Trinity Biobank sample from the Irish Blood Transfusion Service & the Trinity Centre for High Performance Computing. Funding for this study was provided by the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z), the Wellcome Trust (072894/Z/03/Z, 090532/Z/09/Z and 075491/Z/04/B), NIMH grants (MH 41953 and MH083094) and British 1958 Birth Cohort DNA collection funded by the Medical Research Council (grant G0000934) and the Wellcome Trust (grant 068545/Z/02) and of the UK National Blood Service controls funded by the Wellcome Trust. We acknowledge Hong Kong Research Grants Council project grants GRF 774707M, 77511M, 776412M and 776513M.

ENIGMA. ENIGMA was supported in part by a Consortium grant (U54 EB020403 to PMT) from the NIH Institutes contributing to the Big Data to Knowledge (BD2K) Initiative, including the NIBIB and NCI. ADNI and ADNI2GO: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California. BETULA: this sample collection was supported by a Wallenberg Scholar grant from the Knut and Alice Wallenberg (KAW) foundation and a grant from Torsten and Ragnar Söderbergs Foundation to LN, a grant from HelseVest RH (Grant 911554) to SLH. Bipolar Family Study (BFS): The Bipolar Family Study wishes to thank the Scottish Mental Health Research Network for research assistant support, the Brain Research Imaging Centre Edinburgh, a center in the Scottish Funding Council Scottish Imaging Network–A Platform for Scientific Excellence (SINAPSE) Collaboration, for image acquisition and the Wellcome Trust Clinical Research Facility for genotyping.
was supported by the National Alliance for Research on Schizophrenia and Depression (NARSAD) Independent Investigator Award (to A.M.M.), and data collection was supported by the Health Foundation Clinician Scientist Fellowship. BIG: This work makes use of the BIG (Brain Imaging Genetics) database, first established in Nijmegen, The Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud university medical centre and the Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative is supported by the participating departments and centres and by external grants, i.e. the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland, and the Netherlands Organisation for Scientific Research (NWO). We wish to thank all persons who kindly participated in the BIG research. The research leading to these results also receives funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreements #602450 (IMAGEMEND) and #602805 (Aggressotype), and from ERC-2010-ADG 268800-NEUROSChEM. B. Franke is supported by a Vici grant from the Netherlands Organisation for Scientific Research (NWO; grant # 016.130.669).

Brain Genomics Superstruct Project (GSP): Data were provided [in part] by the Brain Genomics Superstruct Project of Harvard University and the Massachusetts General Hospital, with support from the Center for Brain Science Neuroinformatics Research Group, the Athinoula A. Martinos Center for Biomedical Imaging, and the Center for Human Genetic Research. 20 individual investigators at Harvard and MGH generously contributed data to GSP. GIG: The GIG (Genomic Imaging Göttingen) sample was established at the Center for Translational Research in Systems Neuroscience and Psychiatry at Göttingen University. We thank Maria Keil, Esther Dieklof, Tobias Melcher and Ilona Henseler for assistance in MRI data acquisition, and Elisabeth Binder and Holger Mohr for their valuable help with genotyping. We are grateful to all persons who kindly participated in the GIG study. IMAGEN: IMAGEN was supported by the European Union-funded Fp6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT-2007-037286), the fp7 projects IMAGEMEND (602450) and MATRICS (603016), and the Innovative Medicine Initiative Project EU-AIMS (115300-2), the Medical Research Council Programme Grant “Developmental pathways into adolescent substance abuse” (93558), as well as the NIH-biomedical Research Center “Mental Health”. Further support was provided by the Swedish Research Council FORMAS and the German Federal Ministry for Education and Research BMBF (eMED SystAlc 01ZX1311A; Forschungszentrat AERIAL; 1EV0711).

MoodS: The establishment of the MoodS sample was funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network (IG) MoodS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia; grant 01GS08144 to Markus M. Nöthen and Sven Cichon, grant 01GS08147 to Marcella Rietschel and Andreas Meyer-Lindenberg and grant 01GS08148 to Andreas Heinz), under the auspices of the National Genome Research Network plus (NGFNplus), and through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the eMed Programme (grant 01ZX1314A to Markus M. Nöthen, grant 01ZX1314C to Hendrik Walter, grant 01ZX1314G to Marcella Rietschel). MIPP: The MIPP Munich Morphometry Sample comprises images acquired as part of the Munich Antidepressant Response Signature Study and the Recurrent Unipolar Depression (RUD) Case-Control study performed at the MIPP, and control subjects acquired at the Ludwig-Maximilians-University, Munich, Department of Psychiatry. We wish to acknowledge Anna Olynyk and radiographers Rosa Schirmer, Elke Schreiter, Reinhold Borschke and Ines Eider for image acquisition and data preparation. We thank Dorothee P. Auer for local study management in the initial phase of the RUD study. We are grateful to GlaxoSmithKline for providing the genotypes of the Recurrent Unipolar Depression Case-Control Sample. We thank the staff of the Center of Applied Genotyping (CAGT) for generating the genotypes of the MARS cohort. The study is supported by a grant of the Exzellenz-Stiftung of the Max Planck Society. This work has also been funded by the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), FKZ 01GS0481. NCNG: this sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the K.G. Jebsen Foundation, the Research Council of Norway, to SLH, VMS and TE. NESDA: Funding was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 10-000-1002); the Center for Medical Systems Biology (CSMB, NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL), VU University’s Institutes for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam, University Medical Center Groningen, Leiden University Medical Center, National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by Big Grid, the Dutch e-Science Grid, which is financially supported by NWO. NeuroIMAGE: The NeuroIMAGE was supported by NIH Grant R01MH28737 (to Stephen V. Faraone), NWO Large Investment Grant 1750102007010 (to Jan Buitelaar) and grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, and VU University Amsterdam. The research leading to these results also receives funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreements n° 602450 (IMAGEMEND), n° 278948 (TACTICS) and n° 602805 (Aggressotype). NTR-Adults and Brainscale: We would like to thank all twin participants from the Netherlands Twin Register. The NTR-adult and Brainscale studies were supported by the Netherlands Organization for Scientific Research NWO [MW904-61-193 (E.d.G & D.B.), MaGW-nr: 400-07-080 (D. v.t. E.), MagW 480-04-004 (D.B.), 51.02.060 (H.H.), 608.772 (D.B. & H.H.); NWO/SPF 56-464-14192 (D.B.); the European Research Council (ERC-230374) (D.B.), High Potential Grant Utrecht University (H.H.), NWO Brain and Cognition 433-09-220 (H.H.) and the Neuroscience Campus Amsterdam (NCA). Older Australian Twins
Study (OATS): We would like to acknowledge and thank the OATS participants, their supporters and respective Research Teams. This work was supported by a number of sources. OATS is supported by the NHMRC/Australian Research Council Strategic Award 401162 and NHMRC Project Grant 1045325 to P. Sachdev and colleagues. OATS was facilitated through access to the Australian Twin Registry, a national research resource supported by the NHMRC Enabling Grant 310667, administered by the University of Melbourne. DNA was extracted by Genetic Repositories Australia, an Enabling Facility supported by the NHMRC Grant 401184. OATS genotyping was partly funded by a Commonwealth Scientific and Industrial Research Organisation Flagship Collaboration Fund Grant. Henry Brodaty is supported by the Australian Government funded Dementia Collaborative Research Centre (DCRC), UNSW. Nicola Armstrong was supported by the NHMRC Project Grant 525453 and Karen Mather is supported by an Alzheimer’s Australia Dementia Research Foundation Postdoctoral Fellowship and the NHMRC Capacity Building Grant 568940. QTIM: DPH, NJ, CRKC, and PMT are supported, in part, by NIH grants R01 NS080655, R01 AG040060, R01 EB008432, R01 MH07268, U01 AG024904, R01 MH085667, R01 MH089722, P41 EB015922, and R01 MH094343. RKW is supported by National Science Foundation (BCS-1229450). JLS was supported by the NIMH (K09MH102357) and Autism Speaks. SEM and GZ are supported by Future Fellowships (FT110100548, FT0991634) from the Australian Research Council, and GWM is supported by a National Health and Medical Research Council (NHMRC), Australia, Fellowship (619667). The QTIM study is supported by grants from NIH (R01 HD057035) and the NHMRC (389875, 468662, 100964). We thank the twins and siblings for their participation, Marlene Grace and Ann Eldridge for twin recruitment, Aiman Al Najjar and other radiographers for scanning, Kerrie McAloney and Daniel Park for research support, and Anjali Henders and staff for DNA sample processing and preparation. SHIP: The Study of Health in Pomerania (SHIP) is supported by the German Federal Ministry of Education and Research (grants 01ZZ9603, 01ZZ0103 and 01ZZ0403) and the German Research Foundation (DFG; GR 1912/5-1). Genome-wide data and MRI scans were supported by a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg-West Pomerania. SHIP-TREND-0: This cohort is part of the Community Medicine Research net (CMR) of the University of Greifswald, which is funded by the German Federal Ministry of Education and Research and the German Ministry of Cultural Affairs, as well as by the Social Ministry of the Federal State of Mecklenburg-West Pomerania. CMR encompasses several research projects that share data from the population-based Study of Health in Pomerania (SHIP; see URLs). MRI scans were supported by a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg-West Pomerania. The SHIP authors are grateful to Mario Stanke for the opportunity to use his server cluster for SNP imputation as well as to Holger Prokisch and Thomas Meitinger (HelmholtzZentrum München) for genotyping the SHIP-TREND cohort which was supported by the Federal Ministry of Education and Research (grant 03ZIK012). We thank all staff members and participants of the SHIP studies, as well as all of the genotyping staff for generating the SHIP SNP data set. D. J. is supported by a scholarship from the Gerhard Domagk programme of the University Medicine Greifswald. Sydney Memory and Ageing Study (Sydney MAS): We would like to thank the Sydney MAS participants, their supporters and respective Research Teams. Sydney MAS was supported by the Australian National Health and Medical Research Council (NHMRC) Program Grants 350833 and 568969 to P. Sachdev, H. Brodaty and G. Andrews. DNA was extracted by Genetic Repositories Australia, an Enabling Facility supported by the NHMRC Grant 401184. Henry Brodaty is supported by the Australian Government funded Dementia Collaborative Research Centre (DCRC), UNSW. Nicola Armstrong was supported by the NHMRC Project Grant 525453 and Karen Mather is supported by an Alzheimer’s Australia Dementia Research Foundation Postdoctoral Fellowship. Both Simone Reppermund and Karen Mather are supported by the NHMRC Capacity Building Grant 568940.

Data used in preparing this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). Many investigators within ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

PGC-SCZ consortium collaborators include


Nat Neurosci. Author manuscript; available in PMC 2016 August 01.

45 Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, Dublin 8, Ireland

46 Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK

47 Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, London, SE5 8AF, UK

48 NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, 0424 Oslo, Norway

49 Department of Psychiatry, Diakonhjemmet Hospital, 0319 Oslo, Norway

50 Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, SE-17176 Stockholm, Sweden

51 State Mental Hospital, 85540 Haar, Germany

52 Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California 94305, USA

53 Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia 30322, USA
54 Department of Psychiatry and Behavioral Sciences, Atlanta Veterans Affairs Medical Center, Atlanta, Georgia 30033, USA

55 Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA

56 Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen 37075, Germany

57 Department of Medical Genetics, University of Pécs, Pécs H-7624, Hungary

58 Szentagothai Research Center, University of Pécs, Pécs H-7624, Hungary

59 Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA

60 University Medical Center Groningen, Department of Psychiatry, University of Groningen, NL-9700 RB, The Netherlands

61 School of Nursing, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA

62 Center for Brain Science, Harvard University, Cambridge, Massachusetts 02138, USA

63 Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA

64 Athinoula A Martinos Center, Massachusetts General Hospital, Boston, Massachusetts 02129, USA

65 Department of Psychiatry, University of California at San Francisco, San Francisco, California, 94143 USA

66 University Medical Center Utrecht, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, 3584 Utrecht, The Netherlands

67 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

68 Department of Human Genetics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

69 Schizophrenia Research Institute, Sydney NSW 2010, Australia

70 Priority Centre for Translational Neuroscience and Mental Health, University of Newcastle, Newcastle NSW 2300, Australia

71 School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan NSW 2308, Australia
92 Applied Molecular Genomics Unit, VIB Department of Molecular Genetics, University of Antwerp, B-2610 Antwerp, Belgium

93 First Department of Psychiatry, University of Athens Medical School, Athens 11528, Greece

94 Department of Psychiatry, University College Cork, Co Cork, Ireland

95 Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway

96 Cognitive Genetics and Therapy Group, School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Co Galway, Ireland

97 Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, Illinois 60201, USA

98 Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois 60637, USA

99 Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

100 Department of Psychiatry, University of Regensburg, 93053 Regensburg, Germany

101 Folkhälso Research Center, Helsinki, Finland, Biomedicum Helsinki 1, Haartmaninkatu 8, FI-00290, Helsinki, Finland

102 National Institute for Health and Welfare, PO BOX 30, FI-00271 Helsinki, Finland

103 Department of General Practice, Helsinki University Central Hospital, University of Helsinki PO BOX 20, Tukholmankatu 8 B, FI-00014, Helsinki, Finland

104 Translational Technologies and Bioinformatics, Pharma Research and Early Development, FHoffman-La Roche, CH-4070 Basel, Switzerland

105 Mental Health Service Line, Washington VA Medical Center, Washington DC 20422, USA

106 Department of Psychiatry, Georgetown University School of Medicine, Washington DC 20057, USA

107 Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298, USA

108 Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA

109 Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, D-68159 Mannheim, Germany
110 Department of Genetics, University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands

111 Department of Psychiatry, University of Colorado Denver, Aurora, Colorado 80045, USA

112 Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California 90095, USA

113 Departments of Psychiatry and Human Genetics, University of Chicago, Chicago, Illinois 60637 USA

114 Department of Psychiatry, University of Halle, 06112 Halle, Germany

115 Department of Psychiatry, University of Munich, 80336, Munich, Germany

116 Departments of Psychiatry and Human and Molecular Genetics, INSERM, Institut de Myologie, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France

117 Neuroscience Therapeutic Area, Janssen Research and Development, Raritan, New Jersey 08869, USA

118 Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia

119 Academic Medical Centre University of Amsterdam, Department of Psychiatry, 1105 AZ Amsterdam, The Netherlands

120 Illumina, La Jolla, California, California 92122, USA

121 JJ Peters VA Medical Center, Bronx, New York, New York 10468, USA

122 Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

123 School of Electrical Engineering and Computer Science, University of Newcastle, Newcastle NSW 2308, Australia

124 Priority Research Centre for Health Behaviour, University of Newcastle, Newcastle NSW 2308, Australia

125 Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, CH-4058, Switzerland

126 Section of Neonatal Screening and Hormones, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, DK-2300, Denmark

127 Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan
128 Regional Centre for Clinical Research in Psychosis, Department of Psychiatry, Stavanger University Hospital, 4011 Stavanger, Norway

129 Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona, 08035, Spain

130 Centre for Medical Research, The University of Western Australia, Perth, WA 6009, Australia

131 The Perkins Institute for Medical Research, The University of Western Australia, Perth, WA 6009, Australia

132 Department of Medical Genetics, Medical University, Sofia 1431, Bulgaria

133 Department of Psychology, University of Colorado Boulder, Boulder, Colorado 80309, USA

134 Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada

135 Department of Psychiatry, University of Toronto, Toronto, Ontario, M5T 1R8, Canada

136 Institute of Medical Science, University of Toronto, Toronto, Ontario, M5S 1A8, Canada

137 Institute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, Russia

138 Latvian Biomedical Research and Study Centre, Riga, LV-1067, Latvia

139 Department of Psychiatry and Zilkha Neurogenetics Institute, Keck School of Medicine at University of Southern California, Los Angeles, California 90089, USA

140 Faculty of Medicine, Vilnius University, LT-01513 Vilnius, Lithuania

141 Department of Biology and Medical Genetics, 2nd Faculty of Medicine and University Hospital Motol, 150 06 Prague, Czech Republic

142 Department of Child and Adolescent Psychiatry, Pierre and Marie Curie Faculty of Medicine, Paris 75013, France

143 Duke-NUS Graduate Medical School, Singapore 169857, Singapore

144 Department of Psychiatry, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel

145 Centre for Genomic Sciences, The University of Hong Kong, Hong Kong, China

146 Mental Health Centre and Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
147 Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA

148 Department of Psychiatry, Columbia University, New York, New York 10032, USA

149 Department of Mental Health and Substance Abuse Services; National Institute for Health and Welfare, PO BOX 30, FI-00271 Helsinki, Finland

150 Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, 70-453 Szczecin, Poland

151 Department of Biology and Medical Genetics, 2nd Faculty of Medicine and University Hospital Motol, 150 06, Prague, Czech Republic

152 Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA

153 Department of Psychiatry, University of Bonn, D-53127 Bonn, Germany

154 Centre National de la Recherche Scientifique, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Neurodégénératifs, Hôpital de la Pitié Salpêtrière, 75013, Paris, France

155 Research Unit, Sørlandet Hospital, 4604 Kristiansand, Norway

156 Department of Psychiatry, National University of Ireland Galway, Co Galway, Ireland

157 Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, D-68159 Mannheim, Germany

158 Estonian Genome Center, University of Tartu, Tartu 50090, Estonia

159 School of Psychology, University of Newcastle, Newcastle NSW 2308, Australia

160 First Psychiatric Clinic, Medical University, Sofia 1431, Bulgaria

161 Eli Lilly and Company Limited, Erle Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH UK

162 Max Planck Institute of Psychiatry, 80336 Munich, Germany

163 Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK

164 Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany

165 Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin 2, Ireland

166 King's College London, London SE5 8AF, UK
167 Maastricht University Medical Centre, South Limburg Mental Health Research and Teaching Network, EURON, 6229 HX Maastricht, The Netherlands

168 Department of Psychiatry and Psychotherapy, Jena University Hospital, 07743 Jena, Germany

169 Queensland Centre for Mental Health Research, University of Queensland, Brisbane QLD 4076, Australia

170 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA

171 Department of Psychiatry, Trinity College Dublin, Dublin 2, Ireland

172 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, 46285 Indiana, USA

173 Department of Clinical Sciences, Psychiatry, Umeå University, SE-901 87 Umeå, Sweden

174 DETECT Early Intervention Service for Psychosis, Blackrock, Co Dublin, Ireland

175 Centre for Public Health, Institute of Clinical Sciences, Queen's University Belfast, Belfast BT12 6AB, UK

176 Lawrence Berkeley National Laboratory, University of California at Berkeley, Berkeley, California 94720, USA

177 Institute of Psychiatry, King's College London, London SE5 8AF, UK

178 Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Melbourne VIC 3053, Australia

179 Public Health Genomics Unit, National Institute for Health and Welfare, PO BOX 30, FI-00271 Helsinki, Finland

180 Department of Psychiatry, University of Helsinki, PO BOX 590, FI-00029 HUS, Helsinki, Finland

181 PEIC

182 Institute for Molecular Medicine Finland, FIMM, University of Helsinki, PO BOX 20 FI-00014, Helsinki, Finland

183 Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

184 Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK

185 Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA
186 Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois 60637, USA

187 PharmaTherapeutics Clinical Research, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA

188 Department of Psychiatry and Psychotherapy, University of Gottingen, 37073 Gottingen, Germany

189 Psychiatry and Psychotherapy Clinic, University of Erlangen, 91054 Erlangen, Germany

190 Hunter New England Health Service, Newcastle NSW 2308, Australia

191 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA

192 Research and Development, Bronx Veterans Affairs Medical Center, New York, New York 10468, USA

193 Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK

194 Department of Clinical Neurology, Medical University of Vienna, 1090 Wien, Austria

195 Lieber Institute for Brain Development, Baltimore, Maryland 21205, USA

196 Department of Medical Genetics, University Medical Centre Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands

197 Berkshire Healthcare NHS Foundation Trust, Bracknell RG12 1BQ, UK

198 Department of Medical Genetics, Medical University, Sofia1431, Bulgaria

199 Priority Research Centre for Translational Neuroscience and Mental Health, University of Newcastle, Newcastle NSW 2300, Australia

200 Department of Psychiatry, University of Oulu, PO BOX 5000, 90014, Finland

201 University Hospital of Oulu, PO BOX 20, 90029 OYS, Finland

202 Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland

203 Health Research Board, Dublin 2, Ireland

204 Mental Health Centre and Psychiatric Laboratory, West China Hospital, Sichuan University, Chendu, 610041, Sichuan, China

205 School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth WA 6009, Australia
206 Computational Sciences CoE, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA

207 Human Genetics, Genome Institute of Singapore, A*STAR, Singapore 138672, Singapore

208 WTCCC2

209 Division of Psychiatry, University of Edinburgh, Edinburgh EH16 4SB, UK

210 University College London, London WC1E 6BT, UK 211 Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

212 Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, 52428 Juelich, Germany

213 Department of Genetics, The Hebrew University of Jerusalem, 91905 Jerusalem, Israel

214 Neuroscience Discovery and Translational Area, Pharma Research and Early Development, FHoffman-La Roche, CH-4070 Basel, Switzerland

215 School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth, WA 6009, Australia

216 Centre for Clinical Research in Neuropsychiatry, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Medical Research Foundation Building, Perth WA 6000, Australia

217 The Perkins Institute for Medical Research, The University of Western Australia, Perth, WA 6009, Australia

218 The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA

219 The Feinstein Institute for Medical Research, Manhasset, New York 11030, USA

220 The Hofstra NS-LIJ School of Medicine, Hempstead, New York 11549, USA

221 Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117597, Singapore

222 Queensland Brain Institute, The University of Queensland, Brisbane QLD 4072, Australia

223 Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University, Amsterdam 1081, The Netherlands

224 Department of Complex Trait Genetics, Neuroscience Campus Amsterdam, VU University Medical Center Amsterdam, Amsterdam 1081, The Netherlands
ENIGMA2 consortium collaborators include

Franke et al.

228 MRC-SGDP Centre, Institute of Psychiatry, King's College London, London, SE5 8AF, UK

229 Imaging Genetics Center, Institute for Neuroimaging & Informatics, Keck School of Medicine of the University of Southern California, Los Angeles, 90292, USA

230 Institut Pasteur, Paris, 75015, France
231 German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Greifswald, 17487, Germany

232 Department of Psychiatry, University Medicine Greifswald, Greifswald, 17489, Germany

233 Brain Center Rudolf Magnus, Department of Psychiatry, UMC Utrecht, Utrecht, 3584, The Netherlands

234 Umeå Centre for Functional Brain Imaging (UFBI), Umeå University, Umeå, 901 87, Sweden

235 Brain Research Imaging Centre, University of Edinburgh, Edinburgh, EH4 2XU, UK

236 Department of Computer Science, Lagos State University, Lagos, Nigeria

237 Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Department of Neuroimaging Sciences, University of Edinburgh, Edinburgh, EH4 2XU, UK

238 Hospital for Sick Children, University of Toronto, Toronto, M5G 1X8, Canada

239 Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, H4H 1R3, Canada

240 Department of Psychiatry and Biomedical Engineering, McGill University, Montreal, H3A 2B4, Canada

241 Biological Psychology, Neuroscience Campus Amsterdam, VU University & VU Medical Center, Amsterdam, 1081 BT, The Netherlands

242 NORMENT - KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, 5021, Norway

243 Dr Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, 5021, Norway

244 Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6525 XD, The Netherlands

245 International Max Planck Research School for Language Sciences, Nijmegen, 6525 XD, The Netherlands

246 National Institute of Mental Health Intramural Research Program, Bethesda, 20892, USA

247 Center for Neurobehavioral Genetics, University of California, Los Angeles, California, 90095, USA
248 Centre for Cognitive Ageing and Cognitive Epidemiology, Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK

249 Department of Psychiatry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, 1007 MB, The Netherlands

250 Department of Medical and Molecular Genetics, King's College London, London, SE1 9RT, UK

251 Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK

252 Max Planck Institute of Psychiatry, Munich, 80804, Germany

253 Multimodal Imaging Laboratory, Department of Neurosciences, University of California, San Diego, 92093, USA

254 Department of Cognitive Sciences, University of California, San Diego, 92161, USA

255 Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17489, Germany

256 NORMENT - KG Jebsen Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, 0315, Norway

257 NORMENT - KG Jebsen Centre, Department of Psychology, University of Oslo, Oslo, 0373, Norway

258 Molecular and Cellular Therapeutics, The Royal College of Surgeons, Dublin, 2, Ireland

259 The Oxford Center for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, OX3 9DU, UK

260 Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada

261 UCL Institute of Neurology, London, United Kingdom and Epilepsy Society, WC1N 3BG, UK

262 Department of Medicine, Imperial College London, London, SW7 2AZ, UK

263 Department of Psychiatry, Yale University, New Haven, Connecticut, 06511, USA

264 Olin Neuropsychiatric Research Center, Hartford, Connecticut, 06114, USA

265 Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, 12713, Saudi Arabia

266 Texas Biomedical Research Institute, San Antonio, Texas, 78227, USA
267 National Ageing Research Institute, Royal Melbourne Hospital, Melbourne, 3052, Australia

268 Academic Unit for Psychiatry of Old Age, University of Melbourne, 3101, Australia

269 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 20892, USA

270 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH4 2XU, UK

271 NI Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, 119333, Russia

272 Clinical Research Branch, National Institute on Aging, Baltimore, Maryland, 20892, USA

273 University of Texas Health Science Center, San Antonio, 78229, USA

274 Biofunctional Imaging, Immunology Frontier Research Center, Osaka University, Osaka, 565-0871, Japan

275 Harvard Medical School, Cambridge, Massachusetts, 02115, USA

276 Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, 02115, USA

277 Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, 9700, The Netherlands

278 Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, 17489, Germany

279 Department of Psychology, VU University Amsterdam, Amsterdam, 1081 BT, The Netherlands

280 Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, 17489, Germany

281 Radiology, Mayo Clinic, Rochester, Minnesota, 55905, USA

282 FMRIB Centre, University of Oxford, Oxford, OX3 9DU, UK

283 NICHD Brain and Tissue Bank for Developmental Disorders, University of Maryland Medical School, Baltimore, Maryland, 21201, USA

284 School of Psychology, University of Sussex, Brighton, BN1 9QH, UK

285 Institute of Cognitive Neuroscience, University College London, London, WC1N 3AR, UK
286 Department of Psychiatry, University of Maryland, Catonsville, Maryland, 21201, USA
287 Neuroscience Research Australia, Sydney, 2031, Australia
288 School of Medical Sciences, UNSW, Sydney, 2052, Australia
289 Columbia University Medical Center, New York, 10032, USA
290 Lymphocyte Cell Biology Unit, Laboratory of Immunology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, 21224, USA
291 Centre for Advanced Imaging, University of Queensland, Brisbane, 4072, Australia
292 Ludwig-Maximilians-Universität, Munich, 80539, Germany
293 Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
294 Department of Neurology, University of Calgary, Calgary, T2N 2T9, Canada
295 Department of Clinical Neuroscience, University of Calgary, Calgary, T2N 2T9, Canada
296 Psychiatry and Human Behavior, University of California, Irvine, California, 92697, USA
297 Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, USA
298 Department of Neurology, Harvard Medical School, Boston, Massachusetts, 02115, USA
299 Department of Neuropathology, MRC Sudden Death Brain Bank Project, University of Edinburgh, Edinburgh, EH8 9AG, UK
300 Laboratory of Neuro Imaging, Institute for Neuroimaging and Informatics, Keck School of Medicine of the University of Southern California, Los Angeles, California, 90033, USA
301 Brain Resource Center, Johns Hopkins University, Baltimore, Maryland, 21287, USA
302 The Scripps Research Institute, Jupiter, Florida, 33458, USA
303 Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands
304 Neuroimaging Centre, University of Groningen, University Medical Center Groningen, Groningen, 9713 AW, The Netherlands
305 Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, 52242, USA
306 Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, SE-141 83, Sweden
307 Research Resources Branch, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 20892, USA

308 Faculty of Life Sciences, University of Manchester, Manchester, M13 9PL, UK

309 Center for Integrative and Translational Genomics, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA

310 Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA

311 The Mind Research Network & LBERI, Albuquerque, New Mexico, 87106, USA

312 Department of ECE, University of New Mexico, Albuquerque, New Mexico, 87131, USA

313 Center for Translational Imaging and Personalized Medicine, University of California, San Diego, 92093, California, USA

314 Departments of Neurosciences, Radiology, Psychiatry, and Cognitive Science, University of California, San Diego, 92093, California, USA

315 Avera Institute for Human Genetics, Sioux Falls, 57108, USA

316 Neurology Division, Beaumont Hospital, Dublin, 9, Ireland

317 Department of Neurology, Hopital Erasme, Universite Libre de Bruxelles, Brussels, 1070, Belgium

318 Janssen Research & Development, Johnson & Johnson, New Jersey, 08560, USA

319 Department of Psychiatry, University of Iowa, Iowa City, 52242, USA

320 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, 17489, Germany

321 Center for Imaging of Neurodegenerative Disease, San Francisco VA Medical Center, University of California, San Francisco, 94121, USA

322 Department of Child Psychiatry, Erasmus University Medical Centre, Rotterdam, 3015 CE, The Netherlands

323 Department of Radiology, Erasmus University Medical Centre, Rotterdam, 3015 CE, The Netherlands

324 Clinical Neuroimaging Laboratory, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, SW4 794, Ireland

325 Department of Psychiatry and Psychotherapy, HELIOS Hospital Stralsund, 18435, Germany
326 Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, 565-0871, Japan

327 Medical University of Lodz, Lodz, 90-419, Poland

328 Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, 06123, Italy

329 Rotman Research Institute, University of Toronto, Toronto, M6A 2E1, Canada

330 Departments of Psychology and Psychiatry, University of Toronto, M5T 1R8, Canada

331 Departments of Physiology and Nutritional Sciences, University of Toronto, M5S 3E2, Canada

332 Department of Neuroimaging, Institute of Psychiatry, King’s College London, London, SE5 8AF, UK

333 Biomedical Research Centre for Mental Health, King’s College London, London, SE5 8AF, UK

334 Biomedical Research Unit for Dementia, King’s College London, London, SE5 8AF, UK

335 Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, FI-70211, Finland

336 Neurocentre Neurology, Kuopio University Hospital, FI-70211, Finland

337 Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, 3015 GE, The Netherlands

338 Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, 20892, USA

339 Department of Neurology, Clinical Division of Neurogeriatrics, Medical University Graz, Graz, 8036, Austria

340 INSERM U897, University of Bordeaux, 33076, France

341 Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118, USA

342 Framingham Heart Study, Framingham, 01702, USA

343 Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA

344 Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA
References


5. van Erp TG, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2015


Summary

The authors defined a roadmap for the investigation of the genetic covariance between structural/functional brain phenotypes and risk for psychiatric disorders. Their proof-of-concept study using the largest available common variant datasets for schizophrenia and volumes of several (mainly subcortical) brain structures did not find evidence of genetic overlap.
Figure 1.
Genetic predisposition score analyses examining the predictive capacity of ENIGMA brain volumetric results on schizophrenia case-control status using different $P$-value thresholds. X-axis: (a) hippocampus, (b) ICV, (c) nucleus accumbens, (d) amygdala, (e) caudate nucleus, (f) pallidum, (g) putamen, (h) thalamus. Y-axis shows Nagelkerke’s $R^2$. Positive values indicate SNP effects for increasing brain structure volume and increased risk for schizophrenia. Negative values indicate SNP effects for decreasing brain structure volume in and increased risk for schizophrenia. Significance values are given in Table 2.
Figure 2.
Evaluating the genome-wide overlap between genetic influences on schizophrenia and subcortical volumes. (a) A cartoon describing the output map. (b-i) independent SNPs present in both ENIGMA and PGC schizophrenia results were selected independent of association to any phenotype (see on-line methods). Association results were ordered based on the significance of their association to the phenotype (−log\(_{10}(P\text{-value})\) multiplied by the sign of the effect), and statistical significance was evaluated using RRHO test. The same test for overlap was conducted with a (j) finger whorl phenotype, expected to have no overlap with brain structure genetics, and (k) the overlap between caudate and putamen volume, expected to have very strong overlap. Overlap in the rank-ordered lists between genetic variants influencing any of the eight brain phenotypes and those creating risk for schizophrenia was not statistically significant. The overlap between hippocampal volume and presence of a whorl on the left thumb was used as a negative control and showed similar levels of overlap to brain structure and schizophrenia.
Table 1

SNP-heritability analyses for MRI brain volume and genetic correlations with schizophrenia *

<table>
<thead>
<tr>
<th>Brain region</th>
<th>N</th>
<th>Heritability</th>
<th>SE</th>
<th>Genetic correlation with SCZ</th>
<th>SE</th>
<th>Z</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial volume</td>
<td>9,826</td>
<td>0.157</td>
<td>0.050</td>
<td>-0.010</td>
<td>0.072</td>
<td>-0.137</td>
<td>0.891</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>11,624</td>
<td>0.260</td>
<td>0.043</td>
<td>-0.095</td>
<td>0.057</td>
<td>-1.674</td>
<td>0.094</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>11,621</td>
<td>0.135</td>
<td>0.041</td>
<td>-0.147</td>
<td>0.081</td>
<td>-1.826</td>
<td>0.068</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>11,603</td>
<td>0.105</td>
<td>0.045</td>
<td>-0.094</td>
<td>0.090</td>
<td>-1.051</td>
<td>0.293</td>
</tr>
<tr>
<td>Pallidum</td>
<td>11,595</td>
<td>0.137</td>
<td>0.047</td>
<td>-0.038</td>
<td>0.069</td>
<td>-0.546</td>
<td>0.585</td>
</tr>
<tr>
<td>Putamen</td>
<td>11,598</td>
<td>0.303</td>
<td>0.052</td>
<td>0.013</td>
<td>0.052</td>
<td>0.256</td>
<td>0.798</td>
</tr>
<tr>
<td>Thalamus</td>
<td>11,646</td>
<td>0.118</td>
<td>0.041</td>
<td>-0.113</td>
<td>0.087</td>
<td>-1.298</td>
<td>0.194</td>
</tr>
</tbody>
</table>

* amygdala heritability was too low to allow a valid analysis
Table 2

Two outcome variables derived from genetic predisposition analysis.

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>P</th>
<th>$R^2$</th>
<th>AUC</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial volume</td>
<td>0.247</td>
<td>$-2.46 \times 10^{-5}$</td>
<td>0.512</td>
<td>0.944 (0.877,1.016)</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>0.033</td>
<td>$-8.35 \times 10^{-5}$</td>
<td>0.502</td>
<td>0.928 (0.864,0.997)</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.010</td>
<td>$-1.23 \times 10^{-4}$</td>
<td>0.506</td>
<td>0.917 (0.853,0.986)</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>0.002</td>
<td>$-1.74 \times 10^{-4}$</td>
<td>0.500</td>
<td>0.928 (0.862,0.9996)</td>
</tr>
<tr>
<td>Pallidum</td>
<td>0.985</td>
<td>$6.21 \times 10^{-9}$</td>
<td>0.513</td>
<td>1.034 (0.963,1.111)</td>
</tr>
<tr>
<td>Putamen</td>
<td>0.607</td>
<td>$-4.87 \times 10^{-6}$</td>
<td>0.515</td>
<td>0.971 (0.891,1.059)</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.221</td>
<td>$-2.75 \times 10^{-5}$</td>
<td>0.510</td>
<td>0.959 (0.888,1.036)</td>
</tr>
<tr>
<td>Amygdala</td>
<td>0.806</td>
<td>$1.11 \times 10^{-6}$</td>
<td>0.509</td>
<td>1.021 (0.951,1.096)</td>
</tr>
</tbody>
</table>

P=significance uncorrected for multiple testing. $R^2$=correlation (Nagelkerke) on the observed scale corrected for principal components. AUC=area under receiver operating characteristic curve. OR=odds ratio. CI=confidence interval.
Table 3

Sign tests of directional effects among 94 genome-wide significant associations with schizophrenia (P<5×10^{-8}) and the top 231 associations (P<1×10^{-6}).

<table>
<thead>
<tr>
<th>Brain region</th>
<th>(P) threshold</th>
<th>(N) same direction</th>
<th>Proportion</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial volume</td>
<td>&lt;5×10^{-8}</td>
<td>49</td>
<td>0.52</td>
<td>0.379</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>&lt;5×10^{-8}</td>
<td>47</td>
<td>0.50</td>
<td>0.541</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>&lt;5×10^{-8}</td>
<td>46</td>
<td>0.49</td>
<td>0.621</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>&lt;5×10^{-8}</td>
<td>48</td>
<td>0.51</td>
<td>0.459</td>
</tr>
<tr>
<td>Pallidum</td>
<td>&lt;5×10^{-8}</td>
<td>51</td>
<td>0.54</td>
<td>0.235</td>
</tr>
<tr>
<td>Putamen</td>
<td>&lt;5×10^{-8}</td>
<td>52</td>
<td>0.55</td>
<td>0.177</td>
</tr>
<tr>
<td>Thalamus</td>
<td>&lt;5×10^{-8}</td>
<td>49</td>
<td>0.52</td>
<td>0.379</td>
</tr>
<tr>
<td>Intracranial volume</td>
<td>&lt;1×10^{-6}</td>
<td>121</td>
<td>0.52</td>
<td>0.255</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>&lt;1×10^{-6}</td>
<td>113</td>
<td>0.49</td>
<td>0.653</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>&lt;1×10^{-6}</td>
<td>105</td>
<td>0.45</td>
<td>0.926</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>&lt;1×10^{-6}</td>
<td>109</td>
<td>0.47</td>
<td>0.821</td>
</tr>
<tr>
<td>Pallidum</td>
<td>&lt;1×10^{-6}</td>
<td>117</td>
<td>0.51</td>
<td>0.448</td>
</tr>
<tr>
<td>Putamen</td>
<td>&lt;1×10^{-6}</td>
<td>115</td>
<td>0.50</td>
<td>0.552</td>
</tr>
<tr>
<td>Thalamus</td>
<td>&lt;1×10^{-6}</td>
<td>115</td>
<td>0.50</td>
<td>0.552</td>
</tr>
<tr>
<td>Amygdala</td>
<td>&lt;1×10^{-6}</td>
<td>109</td>
<td>0.47</td>
<td>0.821</td>
</tr>
</tbody>
</table>

The expected proportion under the null is 0.5.